Results 161 to 170 of about 310,786 (327)

Enzymatic Remodelling of Tumour Microenvironment Enhances Anti‐CEACAM5 CAR T‐Cell Efficacy Against Colorectal Cancer

open access: yesAdvanced Science, EarlyView.
This study shows anti‐CEACAM5 CAR T‐cells are ineffective against colorectal cancer (CRC) because of CEACAM5 sequestration at intercellular junctions and the thick tumour cell glycocalyx. Enzymatic treatments of CRC cell monolayer/tissue section with trypsin or hyaluronidase restore CEACAM5 availability, enhance CAR T‐cell activation, increase ...
Debasis Banik   +13 more
wiley   +1 more source

Safety and Efficacy of Adoptive Transfer of Stem Cell Memory Enriched Virus Specific T Cells against CMV and EBV

open access: yesAdvanced Science, EarlyView.
This study finds that CD8⁺ TSCM cells exhibit superior self‐renewal, differentiation, and antiviral activity. Transcriptome and epigenome analyses highlight MAPK cascade regulation in TSCM cells. In vivo, virus‐specific TSCM cells show enhanced persistence and tumor protection.
Xun‐Hong Cao   +13 more
wiley   +1 more source

CD103+CD8+ tissue‐resident memory T lymphocytes of melanoma boost anti‐tumour immunity and predict immunotherapy outcomes

open access: yesClinical and Translational Medicine
Background Immunotherapy has revolutionised melanoma treatment, providing significant clinical benefits by reactivating the anti‐tumour immune system. CD8+ tissue‐resident memory T lymphocytes (CD8+ TRM) have emerged as crucial mediators of anti‐tumour ...
Tianyi Zhang   +19 more
doaj   +1 more source

Humphrey Center News: Spring/Summer 1986 v. 2, no. 2 [PDF]

open access: yes, 1986
Newsletter of the Hubert H.
Beldekas, John C.   +3 more
core  

Precise Regulation of Membrane Proteins: From Physical Technology to Biomolecular Strategy

open access: yesAdvanced Science, EarlyView.
This review summarizes the emerging strategies for the precise regulation of membrane proteins using physical stimuli and biomolecule‐based tools. These methods provide new insights into cell regulation and offer promising directions for future disease treatment.
Xiu Zhao   +6 more
wiley   +1 more source

Supplementary Figure 3 from A Universal Strategy for Adoptive Immunotherapy of Cancer through Use of a Novel T-cell Antigen Receptor

open access: gold, 2023
Katarzyna Urbańska   +8 more
openalex   +1 more source

PARPi Combining Nanoparticle LIN28B siRNA for the Management of Malignant Ascites

open access: yesAdvanced Science, EarlyView.
This study demonstrates that co‐inhibition of LIN28B and PARP using siLin28b/DSSP@lip‐PEG‐FA nanoparticles in combination with the PARP inhibitor BMN673 effectively suppresses the accumulation of malignant ascites associated with advanced cancers.
Yan Fang   +13 more
wiley   +1 more source

Supplementary Figure 3 from BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy

open access: gold, 2023
Richard C. Koya   +10 more
openalex   +1 more source

Characterizing Stage‐Specific Cellular Dynamics and Microenvironmental Remodeling in Lung Adenocarcinoma by Single‐Cell RNA Sequencing

open access: yesAdvanced Science, EarlyView.
This study integrated early‐stage patient specimens with publicly available datasets encompassing non‐malignant lung tissues and advanced‐stage LUAD through single‐cell sequencing, revealing a dynamically remodeled tumor microenvironment characterized by a hypoxia‐adapted malignant subset (C5), immunosuppressive LGMN+ macrophages, STAT1‐driven ...
Bomiao Qing   +10 more
wiley   +1 more source

Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors. [PDF]

open access: yes, 2019
The tremendous clinical success of immune checkpoint inhibition (ICI), particularly targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1/2 (PD-L1/2) pathway, has resulted in application to multiple cancers, as a monotherapy and ...
Le, Catherine T, Murphy, William J
core   +1 more source

Home - About - Disclaimer - Privacy